When a husband can slash his wife’s $13,000-a-month cancer prescription down to about forty dollars by clicking a different website, it exposes just how broken America’s drug-pricing machine really is.
Story Snapshot
- A terminal cancer drug quoted at $13,000 per month was found for under $40 through a transparent “cost plus” pharmacy.
- Peer‑reviewed oncology research shows Medicare could save over 80 percent on selected cancer drugs using this model.[1]
- The current cartel of middlemen, rebates, and opaque markups leaves seniors, families, and taxpayers paying wildly inflated prices.[1]
- Trump‑era reforms and conservative pressure on Congress could pair this transparency with regulatory rollbacks to finally confront Big Pharma and its middlemen.
One Family’s Shock: From $13,000 to $40 for the Same Cancer Drug
A husband shopping for his terminally ill wife’s cancer medicine was told the monthly cost of imatinib could run around $13,000 out of pocket, a sum that would bankrupt most families long before the disease ran its course. Yet by checking Mark Cuban’s Cost Plus Drugs, he saw a transparent quote around forty dollars for a similar month’s supply, with a detailed breakdown showing manufacturing, pharmacy labor, and shipping costs instead of mysterious add‑ons.[1]
Reports show that on May 12, a thirty‑day supply of 400 milligrams of imatinib was listed at $39.75 through Cost Plus Drugs, including $25.65 for manufacturing, $3.85 for the company’s fee, five dollars for the pharmacist, and $5.25 for shipping, while the same medicine’s retail cash price was listed at $9,657.30.[1] Separate reporting describes how list prices for imatinib in the traditional system can range from about $4,400 up to over $70,000 per month, depending on who touches it.[1]
How “Cost Plus” Blows Up the Excuses of the Drug-Pricing Cartel
Cost Plus Drugs posts a simple formula: the company takes the acquisition cost of a generic drug, adds a fixed fifteen percent markup, then tacks on modest, clearly labeled fees for pharmacy work and shipping. The firm openly publishes a searchable catalog where patients can compare prices drug by drug and see the spread between its price and typical retail figures, such as abiraterone acetate, a prostate‑cancer medicine, offered at a home‑delivery price far below its listed retail amount.
Peer‑reviewed oncology research has now used those publicly posted prices to model what would happen if Medicare Part D could buy certain cancer drugs the same way. One 2024 analysis in The Oncologist looked at seven cancer‑directed medicines and twenty‑six supportive drugs, finding that if Medicare Part D used Cost Plus pricing for ninety‑count fills, taxpayers could save about $857.8 million, or ninety‑one percent, on the cancer drugs and another $28.7 million, or sixty‑seven percent, on supportive therapies.[1]
Taxpayer Savings, Seniors’ Survival, and the Limits of the New Model
A separate oncology cost comparison examined nine selected cancer medicines and estimated that Medicare Part D and Part B spending of $1.21 billion on those drugs could drop to between $203 million and $147 million if they were bought at Cost Plus Drugs list prices, an eighty‑three to eighty‑eight percent reduction. Vanderbilt University Medical Center summarized related work by noting that Cuban’s model could save taxpayers millions on Medicare generic oncology drugs alone.[2]
These are modeled savings, not yet nationwide reality, and they mainly apply to generics and a limited group of cancer drugs, not brand‑new patented therapies or every injectable treatment.[1] Still, even that narrow slice tells a powerful story: when middlemen and hidden rebates are stripped away, the “true” cost of many lifesaving drugs is a tiny fraction of what American patients and seniors get billed, and the legacy system has not produced hard evidence that these wild markups are necessary to ensure quality or supply.[1]
What Conservatives Should Demand Next from Washington and the States
For years, Republicans and conservatives have warned that a swamp of pharmacy benefit managers, insurer middlemen, and federal red tape drives up drug prices while shielding everyone involved from accountability. The Cost Plus example gives hard numbers to that critique, but it remains a niche workaround unless Congress and regulators open the system so Medicare plans, private insurers, and independent pharmacists can actually use transparent acquisition‑plus pricing at scale without being punished by the rebate cartel.[1][2]
TY to Cost Plus Drugs & Mark Cuban. 👍
His wife’s terminal cancer drug was quoted at $13,000 monthly. He found it for $40 https://t.co/UN3ZtZqZIF
— Rebecca Clester (@ClesterRebecca) May 13, 2026
Trump’s second‑term health team can build on this momentum by pushing Congress to force sunshine onto pharmacy benefit manager contracts, legalize wider direct‑purchase options inside Medicare and employer plans, and clear away Food and Drug Administration and other bureaucratic obstacles that keep cheaper generics and biosimilars off the market.[1] For families staring down five‑figure monthly cancer bills, this is not a venture‑capital hobby; it is about whether ordinary Americans can afford to fight for their lives in a system that honors free markets, transparency, and human dignity.
Sources:
[1] Web – Oncology drug pricing: potential Medicare savings on cancer …
[2] Web – Mark Cuban’s Drug Company Can Reduce Medicare Spending on …
